NASDAQ:CNAT Conatus Pharmaceuticals (CNAT) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free CNAT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.35▼$0.3550-Day Range$0.56▼$1.3452-Week Range$0.23▼$1.07Volume55,183 shsAverage Volume1.28 million shsMarket Capitalization$11.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Conatus Pharmaceuticals alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Conatus Pharmaceuticals Stock (NASDAQ:CNAT)Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 CNAT Stock News HeadlinesApril 3, 2023 | thestreet.comConatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial ResultsAugust 30, 2022 | thestreet.com2015 Biotech Drug/Stock Outlook: Here's What You Need to KnowSee More Headlines Receive CNAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2020Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CNAT CUSIPN/A CIK1383701 Webwww.conatuspharma.com Phone858-376-2600FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,390,000.00 Net Margins-52.42% Pretax MarginN/A Return on Equity-48.22% Return on Assets-39.32% Debt Debt-to-Equity RatioN/A Current Ratio16.28 Quick Ratio16.28 Sales & Book Value Annual Sales$21.72 million Price / Sales0.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book0.66Miscellaneous Outstanding Shares33,170,000Free FloatN/AMarket Cap$11.61 million OptionableNot Optionable Beta1.84 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Steven J. Mento (Age 67)Co-Founder, Pres, CEO & Director Dr. Keith W. Marshall MBA (Age 51)Ph.D., Exec. VP, COO & CFO Dr. David T. Hagerty (Age 64)Exec. VP of Clinical Devel. Dr. Alfred P. Spada (Age 61)Co-Founder, Exec. VP of R&D and Chief Scientific Officer Mr. Alan R. EngbringExec. Director of Investor Relations & Corp. CommunicationsKey CompetitorsNeuroBo PharmaceuticalsNASDAQ:NRBOAvalo TherapeuticsNASDAQ:AVTXAytu BioPharmaNASDAQ:AYTUPieris PharmaceuticalsNASDAQ:PIRSOrgenesisNASDAQ:ORGSView All Competitors CNAT Stock Analysis - Frequently Asked Questions How were Conatus Pharmaceuticals' earnings last quarter? Conatus Pharmaceuticals Inc (NASDAQ:CNAT) released its earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Conatus Pharmaceuticals had a negative net margin of 52.42% and a negative trailing twelve-month return on equity of 48.22%. What other stocks do shareholders of Conatus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Dextera Surgical (DXTR), Novavax (NVAX), Exelixis (EXEL) and Geron (GERN). This page (NASDAQ:CNAT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
